Budesonide Orodispersible Tablet vs. Placebo in Active Eosinophilic Esophagitis
Status:
Completed
Trial end date:
2016-10-04
Target enrollment:
Participant gender:
Summary
The purpose of this study is to prove the superiority of a 6-weeks treatment with budesonide
effervescent tablets versus placebo for the induction of clinico-pathological remission in
patients with acute eosinophilic esophagitis.